OCT 130401
Alternative Names: OCT-130401Latest Information Update: 26 Apr 2023
At a glance
- Originator Oxford Cannabinoid Technologies
- Class Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Trigeminal neuralgia
Most Recent Events
- 10 Apr 2023 OCT 130401 is available for licensing as of 10 Apr 2023. https://www.oxcantech.com/research-and-development
- 10 Apr 2023 Preclinical trials in Trigeminal neuralgia in United Kingdom (Inhalation) (Oxford Cannabinoid Technologies pipeline, April 2023).
- 10 Apr 2023 Oxford Cannabinoid Technologies plans a phase I trial (In volunteers) for Trigeminal neuralgia in Australia (Inhalation) in 2023 (Oxford Cannabinoid Technologies pipeline, April 2023)